Literature DB >> 15562983

Increased tidal volume variability in children is a better marker of opioid-induced respiratory depression than decreased respiratory rate.

Sean J Barbour1, Christine A Vandebeek, J Mark Ansermino.   

Abstract

OBJECTIVE: During opioid administration, decreasing respiratory rate is typically used as a predictor of respiratory depression. Prior to opioid-induced apnea, progressively irregular breathing patterns have been noticed. We hypothesize that opioid administration to children will increase tidal volume variability (TV(var)) and that this will be a better predictor of respiratory depression than a decrease in respiratory rate.
METHODS: We recruited 32 children aged 2-8 years scheduled to undergo surgery. During spontaneous ventilation, flow rates and respiratory rates were continuously recorded, while remifentanil was infused at stepwise increasing doses each lasting 10 min. The infusion was continued until the patient showed signs of respiratory depression. Flow data from each dose was used to calculate tidal volumes, from which TV(var) was calculated. The respiratory rate and TV(var) during the last (D(last)), second to last (D-2), and third to last (D-3), administered doses were compared to those during baseline (fourth to last dose). We chose a threshold of TV(var) increase and compared it to a decrease in respiratory rate below 10 breaths per min as predictors of respiratory depression.
RESULTS: Compared to baseline, the TV(var) increased by 336% and 668% during D(-2) and D(last), respectively, whereas respiratory rate decreased by 14.3%, 31.7%, and 55.5% during D(-3), D(-2), and D(last), respectively. A threshold increase in TV(var) of 150% over baseline correctly predicted respiratory depression in 41% of patients, compared to a drop in respiratory rate correctly predicting 22% of patients.
CONCLUSIONS: TV(var) increases as children approach opioid-induced respiratory depression. This is a more useful predictor of respiratory depression than a fall in respiratory rate because the TV(var) increase is 10 times the drop in respiratory rate. A TV(var) increase also correctly predicts respiratory depression twice as often as decreased respiratory rate and is independent of age-related alterations in physiologic respiratory rates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15562983     DOI: 10.1023/b:jocm.0000042922.63647.b9

Source DB:  PubMed          Journal:  J Clin Monit Comput        ISSN: 1387-1307            Impact factor:   2.502


  9 in total

1.  Do the high-frequency indexes of HRV provide a faithful assessment of cardiac vagal tone? A critical theoretical evaluation.

Authors:  Erez Pyetan; Solange Akselrod
Journal:  IEEE Trans Biomed Eng       Date:  2003-06       Impact factor: 4.538

2.  Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.

Authors:  J F Hoke; D Shlugman; M Dershwitz; P Michałowski; S Malthouse-Dufore; P M Connors; D Martel; C E Rosow; K T Muir; N Rubin; P S Glass
Journal:  Anesthesiology       Date:  1997-09       Impact factor: 7.892

3.  Opioid-induced respiratory depression is associated with increased tidal volume variability.

Authors:  T Bouillon; J Bruhn; H Roepcke; A Hoeft
Journal:  Eur J Anaesthesiol       Date:  2003-02       Impact factor: 4.330

4.  Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures.

Authors:  A K Ross; P J Davis; G L Dear Gd; B Ginsberg; F X McGowan; R D Stiller; L G Henson; C Huffman; K T Muir
Journal:  Anesth Analg       Date:  2001-12       Impact factor: 5.108

5.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

6.  The safety and efficacy of parent-/nurse-controlled analgesia in patients less than six years of age.

Authors:  C L Monitto; R S Greenberg; S Kost-Byerly; R Wetzel; C Billett; R M Lebet; M Yaster
Journal:  Anesth Analg       Date:  2000-09       Impact factor: 5.108

7.  The pharmacodynamic effect of a remifentanil bolus on ventilatory control.

Authors:  H D Babenco; P F Conard; J B Gross
Journal:  Anesthesiology       Date:  2000-02       Impact factor: 7.892

8.  Patient-controlled analgesia with low dose background infusions after lower abdominal surgery in children.

Authors:  E Doyle; I Harper; N S Morton
Journal:  Br J Anaesth       Date:  1993-12       Impact factor: 9.166

9.  Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.

Authors:  M Dershwitz; J F Hoke; C E Rosow; P Michałowski; P M Connors; K T Muir; J L Dienstag
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

  9 in total
  5 in total

Review 1.  Are opioids associated with sleep apnea? A review of the evidence.

Authors:  James M Walker; Robert J Farney
Journal:  Curr Pain Headache Rep       Date:  2009-04

2.  Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.

Authors:  James M Walker; Robert J Farney; Steven M Rhondeau; Kathleen M Boyle; Karen Valentine; Tom V Cloward; Kevin C Shilling
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

3.  Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone.

Authors:  Jason Boland; Elaine Boland; David Brooks
Journal:  Clin Med (Lond)       Date:  2013-04       Impact factor: 2.659

4.  Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study.

Authors:  Katri Elina Clemens; Ines Quednau; Eberhard Klaschik
Journal:  Support Care Cancer       Date:  2008-08-22       Impact factor: 3.603

5.  Buprenorphine differentially alters breathing among four congenic mouse lines as a function of dose, sex, and leptin status.

Authors:  Zachary T Glovak; Chelsea Angel; Christopher B O'Brien; Helen A Baghdoyan; Ralph Lydic
Journal:  Respir Physiol Neurobiol       Date:  2021-12-23       Impact factor: 1.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.